Recently, dexpramipexole (RPPX) was advanced into human ALS clinical trials without the benefit of published, rigorous preclinical testing in models relating to either SOD1 or RNA binding protein–mediated neurodegeneration. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.